Aimee Sznewajs
Overview
Explore the profile of Aimee Sznewajs including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
147
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sun V, Chappell-Campbell L, Blankenburg R, Sznewajs A
Clin Pediatr (Phila)
. 2023 Sep;
63(5):633-641.
PMID: 37776239
Multiple professional societies have emphasized the importance of professional development for physicians. This qualitative study aimed to explore pediatric hospitalists' perceptions of professional development needs and to refine a framework...
2.
Sznewajs A, Pon E, Matthay K
Pediatr Blood Cancer
. 2019 Jul;
66(10):e27901.
PMID: 31264798
Malformation syndromes with predisposition to peripheral neuroblastic tumors (pNT), including neuroblastoma, ganglioneuroblastoma, and ganglioneuroma, may provide clues to critical mutations influencing pNT development. Our objective was to identify and characterize...
3.
Oza S, Boscardin C, Wamsley M, Sznewajs A, May W, Nevins A, et al.
Med Teach
. 2014 Oct;
37(10):915-25.
PMID: 25313933
Background: To understand how third-year medical student interprofessional collaborative practice (IPCP) is affected by self-efficacy and interprofessional experiences (extracurricular experiences and formal curricula). Methods: The authors measured learner IPCP using...
4.
Huang S, Bolch W, Lee C, Van Brocklin H, Pampaloni M, Hawkins R, et al.
Mol Imaging Biol
. 2014 Aug;
17(2):284-94.
PMID: 25145966
Purpose: Iodine-131-m-iodobenzylguanidine ([(131)I]mIBG)-targeted radionuclide therapy (TRT) is a standard treatment for recurrent or refractory neuroblastoma with response rates of 30-40 %. The aim of this study is to demonstrate patient-specific...
5.
Quach A, Ji L, Mishra V, Sznewajs A, Veatch J, Huberty J, et al.
Pediatr Blood Cancer
. 2010 Sep;
56(2):191-201.
PMID: 20830775
Background: (131) I-Metaiodobenzylguanidine ((131) I-MIBG) provides targeted radiotherapy for children with neuroblastoma, a malignancy of the sympathetic nervous system. Dissociated radioactive iodide may concentrate in the thyroid, and (131) I-MIBG...
6.
Gonias S, Goldsby R, Matthay K, Hawkins R, Price D, Huberty J, et al.
J Clin Oncol
. 2009 Jul;
27(25):4162-8.
PMID: 19636009
Purpose: To evaluate the safety and efficacy of high-dose [(131)I]metaiodobenzylguanidine ([(131)I]MIBG) in the treatment of malignant pheochromocytoma (PHEO) and paraganglioma (PGL). Methods: Fifty patients with metastatic PHEO or PGL, age...
7.
Liles A, Blatt J, Morris D, Wardrop 3rd R, Sharma A, Sznewajs A, et al.
Cleve Clin J Med
. 2008 Jul;
75(7):531-9.
PMID: 18646589
Curative therapy for childhood cancers poses the risk of long-term complications, necessitating regular lifelong follow-up for survivors. The Children's Oncology Group (COG) has issued guidelines on this topic (www.survivorshipguidelines.org). This...
8.